PharmGen Science announced on August 21st that it has signed a collaborative research agreement to tackle cancer and intractable rare diseases at the Wide River Institute of Immunology Seoul National University.

The signing ceremony was attended by representatives from the participating institutions including Governor Kim Jin-tae of the Gangwon State, mayor Shin Young-jae of Hongcheon-gun, and Dr Ye Sang-kyu, the director of the research institute.

Under the agreement, PharmGen Science will establish a rapid response system for national crises including infectious disease outbreaks such as COVID-19 and work together to develop and supply therapeutics for cancer and intractable rare diseases.

Based on this, the collaborators set the goal of establishing a joint cooperation system of research and development (R&D), production, and industrialization.

"We will do our best to build a platform for the development of the bioindustry, which will be Korea's main future industry," said Dr Ye Sang-kyu, director of the Wide River Institute of Immunology Seoul National University, "We will make sure that the participating institutions organically cooperate with each other.“

An official from PharmaGen Science said, "As a pharmaceutical company that has joined the National Infectious Disease Rapid Response System, we expect to build organic partnerships throughout the entire development process, including research, production, and licensing, and at the same time, we hope to contribute to the collaboration through our own research and development capabilities for drugs to treat intractable autoimmune diseases."

[WIKI KOREA=Cho Pil Hyun, Staff Reporter]

chop23@wikileaks-kr.org

Cho Pil Hyun, Staff Reporter 다른기사 보기

• facebook
• 트위터
• 카카오톡
• 네이버블로그
• 유튜브